Goldman Sachs’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-979,238
| Closed | -$21M | – | 6654 |
|
|
2026
Q1 | $21M | Sell |
979,238
-526,996
| -35% | -$7.43M | ﹤0.01% | 2390 |
|
|
2025
Q4 | $14M | Buy |
1,506,234
+134,797
| +10% | +$1.13M | ﹤0.01% | 2732 |
|
|
2025
Q3 | $9.67M | Sell |
1,371,437
-319,849
| -19% | -$2.2M | ﹤0.01% | 3006 |
|
|
2025
Q2 | $11M | Buy |
1,691,286
+121,368
| +8% | +$835K | ﹤0.01% | 2673 |
|
|
2025
Q1 | $12.4M | Buy |
1,569,918
+1,097,679
| +232% | +$11.8M | ﹤0.01% | 2481 |
|
|
2024
Q4 | $5.98M | Sell |
472,239
-1,302,068
| -73% | -$18.1M | ﹤0.01% | 3275 |
|
|
2024
Q3 | $24.7M | Sell |
1,774,307
-128,801
| -7% | -$1.84M | ﹤0.01% | 1868 |
|
|
2024
Q2 | $26.2M | Sell |
1,903,108
-234,383
| -11% | -$3.43M | ﹤0.01% | 1665 |
|
|
2024
Q1 | $35.3M | Buy |
2,137,491
+18,642
| +0.9% | +$279K | 0.01% | 1400 |
|
|
2023
Q4 | $30.9M | Buy |
2,118,849
+472,654
| +29% | +$5.73M | 0.01% | 1528 |
|
|
2023
Q3 | $20.2M | Sell |
1,646,195
-746,328
| -31% | -$9.74M | ﹤0.01% | 1790 |
|
|
2023
Q2 | $28.6M | Buy |
2,392,523
+109,187
| +5% | +$1.43M | 0.01% | 1552 |
|
|
2023
Q1 | $30.5M | Buy |
2,283,336
+515,234
| +29% | +$10.1M | 0.01% | 1439 |
|
|
2022
Q4 | $38M | Buy |
1,768,102
+42,960
| +2% | +$881K | 0.01% | 1397 |
|
|
2022
Q3 | $34.6M | Sell |
1,725,142
-169,395
| -9% | -$3.6M | 0.01% | 1392 |
|
|
2022
Q2 | $33.9M | Buy |
1,894,537
+1,863,325
| +5,970% | +$19.2M | 0.01% | 1432 |
|
|
2022
Q1 | $310K | Buy |
31,212
+6,666
| +27% | +$88.1K | ﹤0.01% | 5642 |
|
|
2021
Q4 | $414K | Buy |
+24,546
| New | +$504K | ﹤0.01% | 5489 |
|
|
2021
Q3 | – | Sell |
-11,594
| Closed | -$264K | – | 6275 |
|
|
2021
Q2 | $264K | Buy |
+11,594
| New | +$242K | ﹤0.01% | 5597 |
|
Other funds holding DAWN
Goldman Sachs's DAWN Position: Q2 2026 in Review
Goldman Sachs sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 979,238 shares — an estimated $21M sold.
Goldman Sachs first reported a position in DAWN in Q2 2021 and held it in 19 quarters. The position peaked at $38M in Q4 2022. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Goldman Sachs reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Goldman Sachs sold 979,238 Day One Biopharmaceuticals shares in Q2 2026, an estimated $21M.
- Goldman Sachs first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 19 quarters.
- Goldman Sachs's Day One Biopharmaceuticals position peaked at $38M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.